Lumefantrine, (+)- | CAS#120583-70-2

MedKoo Cat#: 527985 | Name: Lumefantrine, (+)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lumefantrine, (+)- is a bioactive chemical.

Chemical Structure

Lumefantrine, (+)-

CAS#120583-70-2 (+)

Theoretical Analysis

MedKoo Cat#: 527985

Name: Lumefantrine, (+)-

CAS#: 120583-70-2 (+)

Chemical Formula: C30H32Cl3NO

Exact Mass: 527.1549

Molecular Weight: 528.94

Elemental Analysis: C, 68.12; H, 6.10; Cl, 20.11; N, 2.65; O, 3.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

82186-77-4 120583-70-2 (+) 120583-71-3 (-)

Synonym

Lumefantrine, (+)-

IUPAC/Chemical Name

9H-Fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (9Z)-(+)-

InChi Key

DYLGFOYVTXJFJP-MYYYXRDXSA-N

InChi Code

InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-

SMILES Code

OC(CN(CCCC)CCCC)C1=CC(Cl)=CC(/C2=C\C3=CC=C(Cl)C=C3)=C1C4=C2C=C(Cl)C=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 528.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tavul L, Hetzel MW, Teliki A, Walsh D, Kiniboro B, Rare L, Pulford J, Siba PM, Karl S, Makita L, Robinson L, Kattenberg JH, Laman M, Oswyn G, Mueller I. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Malar J. 2018 Oct 5;17(1):350. doi: 10.1186/s12936-018-2494-z. PubMed PMID: 30290825. 2: Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, Dara A, Djimde AA, Doumbo OK. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018 Oct 5;17(1):347. doi: 10.1186/s12936-018-2496-x. PubMed PMID: 30290808. 3: Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, Seidlein LV, Price RN. Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med. 2018 Oct 4;15(10):e1002677. doi: 10.1371/journal.pmed.1002677. eCollection 2018 Oct. PubMed PMID: 30286081. 4: Ankrah D, Hallas J, Odei J, Asenso-Boadi F, Dsane-Selby L, Donneyong M. A review of the Ghana National Health Insurance Scheme claims database: possibilities and limits for drug utilization research. Basic Clin Pharmacol Toxicol. 2018 Sep 27. doi: 10.1111/bcpt.13136. [Epub ahead of print] PubMed PMID: 30260590. 5: Koller R, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound. Expert Opin Investig Drugs. 2018 Oct;27(10):803-810. doi: 10.1080/13543784.2018.1524871. Epub 2018 Sep 25. PubMed PMID: 30223692. 6: Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infect Drug Resist. 2018 Aug 28;11:1329-1338. doi: 10.2147/IDR.S160164. eCollection 2018. PubMed PMID: 30214253; PubMed Central PMCID: PMC6118251. 7: Greenhalgh S, Hobbs CV, Parikh S. Brief Report: Antimalarial Benefit of HIV Antiretroviral Therapy in Areas of Low to Moderate Malaria Transmission Intensity. J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):249-254. doi: 10.1097/QAI.0000000000001783. PubMed PMID: 30212437. 8: Gallay J, Pothin E, Mosha D, Lutahakana E, Mazuguni F, Zuakulu M, Decosterd LA, Genton B. Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania. PLoS One. 2018 Sep 7;13(9):e0202745. doi: 10.1371/journal.pone.0202745. eCollection 2018. PubMed PMID: 30192770; PubMed Central PMCID: PMC6128528. 9: Takaya S, Kutsuna S, Suzuki T, Komaki-Yasuda K, Kano S, Ohmagari N. Case Report: Plasmodium knowlesi Infection with Rhabdomyolysis in a Japanese Traveler to Palawan, the Philippines. Am J Trop Med Hyg. 2018 Oct;99(4):967-969. doi: 10.4269/ajtmh.18-0348. PubMed PMID: 30182921. 10: Banda CG, Dzinjalamala F, Mukaka M, Mallewa J, Maiden V, Terlouw DJ, Lalloo DG, Khoo SH, Mwapasa V. Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy. Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.01162-18. doi: 10.1128/AAC.01162-18. [Epub ahead of print] PubMed PMID: 30150465. 11: Amorha KC, Ugwuowo OB, Ayogu EE, Nduka SO, Okonta MJ. Evaluation of the hepatic effect of concomitant administration of ciprofloxacin and some antimalarial drugs in Plasmodium berghei infected mice: An in vivo study. Pak J Pharm Sci. 2018 Sep;31(5):1805-1811. PubMed PMID: 30150174. 12: Martin RE, Shafik SH, Richards SN. Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite. Curr Opin Pharmacol. 2018 Aug 21;42:71-80. doi: 10.1016/j.coph.2018.07.010. [Epub ahead of print] Review. PubMed PMID: 30142480. 13: Ghimire P, Rijal KR, Kafle C, Karki BS, Singh N, Ortega L, Thakur GD, Adhikari B. Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal. Trop Dis Travel Med Vaccines. 2018 Aug 14;4:9. doi: 10.1186/s40794-018-0068-2. eCollection 2018. PubMed PMID: 30123520; PubMed Central PMCID: PMC6092778. 14: Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018 Aug 16;13(8):e0202082. doi: 10.1371/journal.pone.0202082. eCollection 2018. PubMed PMID: 30114201; PubMed Central PMCID: PMC6095545. 15: Roth JM, Sawa P, Omweri G, Makio N, Osoti V, de Jong MD, Schallig HDFH, Mens PF. Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children. Am J Trop Med Hyg. 2018 Oct;99(4):970-977. doi: 10.4269/ajtmh.18-0233. PubMed PMID: 30105967. 16: Oyebola KM, Aina OO, Idowu ET, Olukosi YA, Ajibaye OS, Otubanjo OA, Awolola TS, Awandare GA, Amambua-Ngwa A. A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria. BMC Infect Dis. 2018 Aug 13;18(1):392. doi: 10.1186/s12879-018-3314-3. PubMed PMID: 30103683. 17: Adegbola A, Abutaima R, Olagunju A, Ijarotimi O, Siccardi M, Owen A, Soyinka J, Bolaji O. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01252-18. doi: 10.1128/AAC.01252-18. Print 2018 Oct. PubMed PMID: 30082286; PubMed Central PMCID: PMC6153791. 18: Raobela O, Andriantsoanirina V, Rajaonera DG, Rakotomanga TA, Rabearimanana S, Ralinoro F, Ménard D, Ratsimbasoa A. Efficacy of artesunate-amodiaquine in the treatment of falciparum uncomplicated malaria in Madagascar. Malar J. 2018 Aug 6;17(1):284. doi: 10.1186/s12936-018-2440-0. PubMed PMID: 30081916; PubMed Central PMCID: PMC6080545. 19: Lohy Das J, Rulisa S, de Vries PJ, Mens PF, Kaligirwa N, Agaba S, Tarning J, Karlsson MO, Dorlo TPC. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00518-18. doi: 10.1128/AAC.00518-18. Print 2018 Oct. PubMed PMID: 30061282; PubMed Central PMCID: PMC6153812. 20: Gondwe T, Robberstad B, Mukaka M, Lange S, Blomberg B, Phiri K. Delivery strategies for malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years old in Malawi: a protocol for a cluster randomized trial. BMC Pediatr. 2018 Jul 20;18(1):238. doi: 10.1186/s12887-018-1199-3. PubMed PMID: 30029620; PubMed Central PMCID: PMC6057552.